Pharmaceuticals Great Chemistry Cures COVID-19: Phase 2 (SPRINT) complete A Proven Approach to Drug Discovery Proven Track Record of Success Strong Balance Sheet 3 | --- | --- | --- | |-------|-------|-------------------------------------------------------------------------------------------------| | | | | | HCV | HBV | viral infections Several therapeutic areas with goal of building multiple approaches in each | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|----------------|- ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Tara Kieffer - Senior Vice President of New Product Strategy and Development Conference Call Participants Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Ed Arce - H.C. Wainwright Eric Joseph - JPMorgan Roy Buchanan - JMP Securities Amy Li - Jefferies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3205099 (State or other jurisdiction of incorporation or organization) 5 ...

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19 • Low frequency of adverse events; most were mild in severity – 1.3%, 6.4%, and 2.6% in the EDP-235 200mg, 400mg and placebo arms Clinical Symptoms – Additional analysis of patients with baseline viral load >5 log showed decline of 0.4 log at day 3 with EDP-235 compared to placebo • Rapid decline in nasal viral RNA observed in all study ar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3205099 (State or other jurisdiction of incorporation or organization) 500 Arsenal Street Watertown, Mas ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Jennifer Viera – Investor Relations Jay Luly – President and Chief Executive Officer Paul Mellett – Chief Financial Officer Tara Kieffer – Senior Vice President-New Product Strategy Development Conference Call Participants Joe Kim – RBC Luke Herrmann – Baird Roanna Ruiz – SVB Securities Matthew Hershenhorn – Oppenheimer Ed Arce – H.C. Wainwright & Co Eric Joseph – JPMorgan Roy Buchana ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3205099 (State or other jurisdiction of incorporation or organizatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 2834 04-3205099 (State or other jurisdiction of incorporation or organization) ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Conference Call November 21, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, Investor Relations & Corporate Communications Jay Luly - President & Chief Executive Officer Paul Mellett - Chief Financial Officer Tara Kieffer - Senior Vice President, New Product Strategy & Development Conference Call Participants Brian Abrahams - RBC Capital Markets Yasmeen Rahimi - Piper Sandler Brian Skorney - Baird Liisa Bayko - Evercore ISI E ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration & CFO Tara Kieffer - SVP, New Product Strategy & Development Conference Call Participants Douglas Buchanan - JMP Securities Brian Skorney - Robert W. Baird & Co. Hannah Adeoye - JPMorgan Chase & Co. Roanna Ruiz - SVB Securities Operator Good a ...